This analysis is based on information available up to January 17, 2025, and market conditions may have changed since then. Gain an edge in your investment decisions with InvestingPro’s in-depth ...
Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...
WCIA Champaign on MSN1d
'Probably going to be the most prescribed drug'; The future of weight loss drugsDrugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss. GLP-1 medications were originally intended to ...
Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...
Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...
A dietetics professor explains who should and should not embrace the latest weight-loss drugs. Holiday weight gain hits home ...
World stocks are mixed follow Wall Street’s mostly positive performance ahead of key U.S. inflation data that could influence ...
Eli Lilly ( LLY -6.59%) is the most valuable healthcare stock in the world, with a market capitalization of around $720 ...
Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...
Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback